Actuate Wins FDA Clearance for Oral Elraglusib Trial
I'm LongbridgeAI, I can summarize articles.Actuate Therapeutics, Inc. has received FDA clearance for its Investigational New Drug application for an oral formulation of elraglusib, allowing a Phase 1/2 trial in advanced solid tumors, including metastatic melanoma and pancreatic cancer, set to begin in late 2026. This transition from IV to oral aims to enhance patient convenience and drug efficacy. The company is also collaborating with the EMA and FDA for a potential registration study and has appointed Martin Huber, MD, to its board. Analysts rate ACTU stock as a Buy with a $15.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actuate Therapeutics, Inc. ( (ACTU) ) has provided an announcement.
On May 11, 2026, Actuate Therapeutics announced that the U.S. FDA cleared its Investigational New Drug application for an oral tablet formulation of elraglusib, enabling a Phase 1/2 trial in advanced solid tumors including metastatic melanoma, NSCLC, colorectal, and pancreatic cancers in the second half of 2026. The strategy builds on Phase 2 data in metastatic pancreatic ductal adenocarcinoma showing higher drug exposure correlated with improved overall survival and aims to improve patient convenience, pharmacokinetics, and broader clinical utility by transitioning from an IV to an oral format.
The company is also working with the EMA and FDA on trial design for a potential single registration study of oral elraglusib in pancreatic cancer, after prior IV combinations with gemcitabine and nab-paclitaxel showed statistically significant survival benefits. In parallel, Actuate is exploring combinations of elraglusib with RAS inhibitors in RAS-driven cancers and has strengthened its governance and oncology development expertise by appointing industry veteran Martin Huber, MD, to its board of directors.
The most recent analyst rating on (ACTU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page.
More about Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers. Its lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting tumor growth, treatment resistance pathways, and potentially anti-tumor immunity, with a particular emphasis on solid tumors such as pancreatic cancer.
Average Trading Volume: 125,300
Technical Sentiment Signal: Sell
Current Market Cap: $78.24M
Find detailed analytics on ACTU stock on TipRanks’ Stock Analysis page.